Menu
Not yet recruiting NCT07602309

Tedlar Bag Stability of Volatile Sulfur Compounds for Remote Halitosis Diagnosis

No phase Interventional Halitosis Periodontal Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Breath sample collection with Tedlar bags PLV 0.6L and plastic syringe 1cc.
Who it may be relevant to
Registry conditions: Halitosis, Periodontal Diseases. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Relevance of Using Tedlar Bags for the Remote Evaluation of the Stability of Volatile Sulfur Compounds in Gaseous Samples for the Diagnosis of Halitosis

Overview

Halitosis, or bad breath, affects about 30% of people worldwide and is most often caused by oral diseases such as periodontitis. To diagnose it, dentists usually perform a clinical examination and measure specific gases in the breath called volatile sulfur compounds (VSCs), which are responsible for bad odor. However, the equipment needed for this analysis is not widely available, forcing many patients to travel long distances. This study aims to determine whether breath samples can be collected and analyzed later, making remote diagnosis possible. Specifically, it evaluates whether the levels of these gases remain stable for up to 7 days after collection, with a variation of less than 20% considered acceptable. To do this, 100 adult patients with periodontal conditions will be included in a single-center study. During a single visit, patients will provide breath samples by exhaling into a special Tedlar bag and a syringe, which will then be analyzed immediately and again after 7 days using a device called OralChroma. Afull periodontal examination will also be performed, and patient information such as age and risk factors will be collected. The study will also examine how gas levels change over time and whether they are linked to gum disease. If the results confirm that the samples remain stable, this approach could allow patients to collect their breath at home and receive a diagnosis remotely, reducing the need for travel and improving access to care.

Interventions

  • Diagnostic test Breath sample collection with Tedlar bags PLV 0.6L and plastic syringe 1cc
    Patients will be asked to collect their own breath sample with two different devices : Tedlar bag 0.6L and plastic syringe 1cc

Primary outcome measures

  • Proportion of patient showing a decrease of 20% of H2S level at day 7 [Time frame: The measurement will be performed at baseline (day 0) and seven days later (day 7)]

Eligibility criteria

Inclusion criteria

Adult subject, male or female

  • Subject affiliated with a health insurance system
  • Subject able to sign the non-opposition form
  • Subject attending a consultation at UF8607 for diagnosis and treatment of a periodontal condition

Exclusion criteria

  • \- Subject under legal protection (judicial safeguard)
  • Subject under guardianship or curatorship
  • Pregnancy or breastfeeding
  • Inability to provide the subject with informed information (e.g., emergency situation, comprehension difficulties)
  • Subject currently enrolled in another clinical research protocol or in an exclusion period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

France · 1 center
  • Clinique Dentaire — Strasbourg

Identifiers

NCT: NCT07602309 · RC25_0120

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗